Compounds > mitotane
Page last updated: 2024-10-31

mitotane and Disease Exacerbation

mitotane has been researched along with Disease Exacerbation in 11 studies

Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Research Excerpts

ExcerptRelevanceReference
"Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce."7.88Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018)
"Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients."7.11Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022)
"Mitotane plasma levels were determined using high-performance liquid chromatography."6.72Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006)
"Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities."5.46Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017)
"Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce."3.88Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018)
"Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients."3.11Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022)
"Treatment of refractory adrenocortical carcinoma (ACC) is not established."2.77Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. ( Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP, 2012)
"Mitotane plasma levels were determined using high-performance liquid chromatography."2.72Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006)
"Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities."1.46Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017)
" Treatment resulted in an improvement of performance status and a reduction of the daily dosage of mitotane in all patients."1.35Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. ( Bizzarri, G; Graziano, FM; Guglielmi, R; Pacella, CM; Pacella, S; Papini, E; Stasi, R, 2008)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's7 (63.64)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Laganà, M1
Grisanti, S1
Ambrosini, R1
Cosentini, D1
Abate, A1
Zamparini, M1
Ferrari, VD1
Gianoncelli, A1
Turla, A1
Canu, L1
Terzolo, M1
Tiberio, GAM1
Sigala, S1
Berruti, A1
Reidy-Lagunes, DL1
Lung, B1
Untch, BR1
Raj, N1
Hrabovsky, A1
Kelly, C1
Gerst, S1
Katz, S1
Kampel, L1
Chou, J1
Gopalan, A1
Saltz, LB1
Megerle, F1
Herrmann, W1
Schloetelburg, W1
Ronchi, CL1
Pulzer, A1
Quinkler, M2
Beuschlein, F1
Hahner, S2
Kroiss, M2
Fassnacht, M2
Xu, Y1
Dong, B1
Huang, J1
Kong, W1
Xue, W1
Zhu, Y1
Zhang, J1
Huang, Y1
Sedhom, R1
Hu, S1
Ohri, A1
Infantino, D1
Lubitz, S1
Fareau, GG1
Lopez, A1
Stava, C1
Vassilopoulou-Sellin, R1
Hubertus, J1
Boxberger, N2
Redlich, A2
von Schweinitz, D1
Vorwerk, P2
Johanssen, S1
van Erp, NP1
Lankheet, N1
Pöllinger, A1
Laubner, K1
Strasburger, CJ1
Müller, HH1
Allolio, B1
Strugala, D1
Frühwald, MC1
Leuschner, I1
Kropf, S1
Bucsky, P1
Zancanella, P1
Pianovski, MA1
Oliveira, BH1
Ferman, S1
Piovezan, GC1
Lichtvan, LL1
Voss, SZ1
Stinghen, ST1
Callefe, LG1
Parise, GA1
Santana, MH1
Figueiredo, BC1
Pacella, CM1
Stasi, R1
Bizzarri, G1
Pacella, S1
Graziano, FM1
Guglielmi, R1
Papini, E1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines[NCT03257891]Phase 225 participants (Anticipated)Interventional2018-01-25Recruiting
Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry[NCT00453674]1,000 participants (Anticipated)Observational2003-01-31Recruiting
Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy[NCT00453895]Phase 239 participants (Actual)Interventional2007-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Assessment of Clinical Benefit Due to Treatment With Sunitinib

Clinical benefit was defined as stable disease or better for at least 12 weeks (NCT00453895)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Sunitinib5

Assessment of Objective Response Rates

Objective Response Rate defined by RECIST 1.0 (NCT00453895)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Sunitinib0

Assessment of Overall Survival

Overall Survival was defined as time from start of treatment until death or last follow-up. (NCT00453895)
Timeframe: up to 36 months

Interventionmonhts (Median)
Sunitinib5.4

Assessment of Progression-free Survival

Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00453895)
Timeframe: up to 400 days

Interventiondays (Median)
Sunitinib83

Assessment of Toxicity

Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html). (NCT00453895)
Timeframe: up to 400 days

Interventionnumber of adverse events/patient (Median)
Sunitinib4

Trials

4 trials available for mitotane and Disease Exacerbation

ArticleYear
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2022
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplast

2012
Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial.
    Klinische Padiatrie, 2012, Volume: 224, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Child; Chil

2012
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Journal of pediatric hematology/oncology, 2006, Volume: 28, Issue:8

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Ch

2006

Other Studies

7 other studies available for mitotane and Disease Exacerbation

ArticleYear
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    The oncologist, 2017, Volume: 22, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and

2017
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2018, 04-01, Volume: 103, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A

2018
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Oncotarget, 2016, Jan-19, Volume: 7, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carci

2016
Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
    Journal of medical case reports, 2016, Oct-12, Volume: 10, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Cushing Syndrome; Disease Progression; Fatal Outcome; Female;

2016
Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
    Anti-cancer drugs, 2008, Volume: 19, Issue:6

    Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease

2008
Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial.
    Klinische Padiatrie, 2012, Volume: 224, Issue:3

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Agents, Hormonal; Chemotherapy,

2012
Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.
    European journal of radiology, 2008, Volume: 66, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modali

2008